Saratoga Research & Investment Management Acquires Shares of 6,962 Eli Lilly and Company (LLY)

Saratoga Research & Investment Management bought a new stake in Eli Lilly and Company (NYSE:LLY) in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 6,962 shares of the company’s stock, valued at approximately $596,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Pathstone Family Office LLC raised its position in shares of Eli Lilly and by 100.0% in the second quarter. Pathstone Family Office LLC now owns 58 shares of the company’s stock valued at $4,774,000 after buying an additional 29 shares during the last quarter. Vantage Financial Partners Ltd. Inc. acquired a new stake in shares of Eli Lilly and in the second quarter valued at about $494,000. Acrospire Investment Management LLC raised its position in shares of Eli Lilly and by 16.7% in the second quarter. Acrospire Investment Management LLC now owns 1,399 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the last quarter. MPS Loria Financial Planners LLC acquired a new stake in shares of Eli Lilly and in the second quarter valued at about $128,000. Finally, San Francisco Sentry Investment Group CA acquired a new stake in shares of Eli Lilly and in the second quarter valued at about $129,000. Institutional investors and hedge funds own 76.43% of the company’s stock.

Eli Lilly and Company (LLY) traded up $0.48 during trading on Wednesday, reaching $86.06. 3,876,700 shares of the company traded hands, compared to its average volume of 3,672,667. Eli Lilly and Company has a 52-week low of $66.39 and a 52-week high of $89.09. The firm has a market capitalization of $94,231.72, a PE ratio of 20.92, a P/E/G ratio of 1.88 and a beta of 0.35. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. Eli Lilly and’s revenue was up 9.0% compared to the same quarter last year. During the same quarter last year, the firm posted $0.88 earnings per share. research analysts anticipate that Eli Lilly and Company will post 4.21 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 8th. Shareholders of record on Wednesday, November 15th will be paid a dividend of $0.52 per share. This represents a $2.08 annualized dividend and a yield of 2.42%. The ex-dividend date of this dividend is Tuesday, November 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.

A number of brokerages have recently commented on LLY. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, October 24th. Barclays increased their target price on shares of Eli Lilly and from $90.00 to $98.00 and gave the company an “overweight” rating in a research report on Friday, October 13th. Berenberg Bank restated a “buy” rating and set a $98.00 price objective on shares of Eli Lilly and in a research report on Thursday, October 26th. Zacks Investment Research cut shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Finally, Cowen restated a “buy” rating and set a $95.00 price objective on shares of Eli Lilly and in a research report on Wednesday, October 4th. Three equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and nine have issued a buy rating to the stock. Eli Lilly and currently has an average rating of “Hold” and a consensus target price of $90.25.

In other Eli Lilly and news, SVP Susan Mahony sold 36,585 shares of the stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the completion of the transaction, the senior vice president now owns 54,885 shares of the company’s stock, valued at $4,729,989.30. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 190,000 shares of the stock in a transaction dated Friday, September 15th. The stock was sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the transaction, the insider now directly owns 123,682,287 shares of the company’s stock, valued at approximately $10,207,499,146.11. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 628,588 shares of company stock valued at $53,399,536. 0.20% of the stock is currently owned by insiders.

ILLEGAL ACTIVITY NOTICE: “Saratoga Research & Investment Management Acquires Shares of 6,962 Eli Lilly and Company (LLY)” was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another site, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this report can be viewed at https://sportsperspectives.com/2017/12/06/saratoga-research-investment-management-acquires-shares-of-6962-eli-lilly-and-company-lly.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply